What Do Tesla Delivery Numbers Mean for Tesla Stock?
Tesla (NASDAQ:TSLA) released Q1 delivery numbers, showing a substantial slowdown…
Sell
30
AKBA Quote, Financials, Valuation and Earnings
Last price:
$1.65
Seasonality move
:
14%
Day range:
$1.54 - $1.68
52-week range:
$0.80 - $2.89
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.17x
P/B ratio:
--
Volume:
4.8M
Avg. volume:
5.6M
1-year change:
7.84%
Market cap:
$431M
Revenue:
$160.2M
EPS (TTM):
-$0.33
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AKBA
Akebia Therapeutics
|
$44.9M | -$0.04 | 36.1% | -50% | $7.38 |
|
CLRB
Cellectar Biosciences
|
-- | -$0.16 | -- | -80.95% | $5.67 |
|
CTMX
CytomX Therapeutics
|
$28.5M | $0.10 | -31.21% | -39.59% | $4.94 |
|
IPA
ImmunoPrecise Antibodies
|
$4.6M | -$0.09 | 15.22% | -45.11% | $4.00 |
|
LFWD
Lifeward
|
$6.4M | -$0.33 | 21.74% | -54.8% | $9.00 |
|
MCRB
Seres Therapeutics
|
$10M | $0.08 | -100% | -55.56% | $4.59 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AKBA
Akebia Therapeutics
|
$1.65 | $7.38 | $431M | -- | $0.00 | 0% | 2.17x |
|
CLRB
Cellectar Biosciences
|
$0.28 | $5.67 | $12.9M | -- | $0.00 | 0% | 730.55x |
|
CTMX
CytomX Therapeutics
|
$0.53 | $4.94 | $42.7M | 1.37x | $0.00 | 0% | 0.33x |
|
IPA
ImmunoPrecise Antibodies
|
$0.43 | $4.00 | $19.7M | -- | $0.00 | 0% | 0.71x |
|
LFWD
Lifeward
|
$1.43 | $9.00 | $15.2M | -- | $0.00 | 0% | 0.48x |
|
MCRB
Seres Therapeutics
|
$0.59 | $4.59 | $103M | -- | $0.00 | 0% | 0.74x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AKBA
Akebia Therapeutics
|
-368.79% | 1.753 | 9.06% | 1.07x |
|
CLRB
Cellectar Biosciences
|
-- | 0.405 | -- | -- |
|
CTMX
CytomX Therapeutics
|
-- | 1.069 | -- | 1.21x |
|
IPA
ImmunoPrecise Antibodies
|
-- | -0.825 | -- | 1.99x |
|
LFWD
Lifeward
|
-- | -0.357 | -- | 1.25x |
|
MCRB
Seres Therapeutics
|
-- | 0.231 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AKBA
Akebia Therapeutics
|
$26.1M | -$14.3M | -9553.8% | -- | -34.25% | -$4.5M |
|
CLRB
Cellectar Biosciences
|
-- | -$12.7M | -- | -- | -- | -$11M |
|
CTMX
CytomX Therapeutics
|
-- | $17.7M | -- | -- | 46.41% | -$20M |
|
IPA
ImmunoPrecise Antibodies
|
$2.3M | -$2.3M | -128.72% | -132.89% | -396.08% | -$783.8K |
|
LFWD
Lifeward
|
$1.8M | -$5.4M | -81.96% | -81.96% | -72.02% | -$4M |
|
MCRB
Seres Therapeutics
|
-- | -$28.8M | -- | -- | -- | -$39M |
Akebia Therapeutics vs. Competitors
-
Which has Higher Returns AKBA or CLRB?
Cellectar Biosciences has a net margin of -49.04% compared to Akebia Therapeutics's net margin of --. Akebia Therapeutics's return on equity of -- beat Cellectar Biosciences's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AKBAAkebia Therapeutics56.2% -$0.10 -$10.5M CLRBCellectar Biosciences-- -$0.01 -- -
What do Analysts Say About AKBA or CLRB?
Akebia Therapeutics has a consensus price target of $7.38, signalling upside risk potential of 346.97%. On the other hand Cellectar Biosciences has an analysts' consensus of $5.67 which suggests that it could grow by 1929.61%. Given that Cellectar Biosciences has higher upside potential than Akebia Therapeutics, analysts believe Cellectar Biosciences is more attractive than Akebia Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings AKBAAkebia Therapeutics2 0 0 CLRBCellectar Biosciences1 1 0 -
Is AKBA or CLRB More Risky?
Akebia Therapeutics has a beta of 0.866, which suggesting that the stock is 13.353% less volatile than S&P 500. In comparison Cellectar Biosciences has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.203%.
-
Which is a Better Dividend Stock AKBA or CLRB?
Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectar Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. Cellectar Biosciences pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKBA or CLRB?
Akebia Therapeutics quarterly revenues are $46.5M, which are larger than Cellectar Biosciences quarterly revenues of --. Akebia Therapeutics's net income of -$22.8M is lower than Cellectar Biosciences's net income of -$2.4M. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while Cellectar Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 2.17x versus 730.55x for Cellectar Biosciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKBAAkebia Therapeutics2.17x -- $46.5M -$22.8M CLRBCellectar Biosciences730.55x -- -- -$2.4M
-
Which has Higher Returns AKBA or CTMX?
CytomX Therapeutics has a net margin of -49.04% compared to Akebia Therapeutics's net margin of 49.55%. Akebia Therapeutics's return on equity of -- beat CytomX Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AKBAAkebia Therapeutics56.2% -$0.10 -$10.5M CTMXCytomX Therapeutics-- $0.23 -$456K -
What do Analysts Say About AKBA or CTMX?
Akebia Therapeutics has a consensus price target of $7.38, signalling upside risk potential of 346.97%. On the other hand CytomX Therapeutics has an analysts' consensus of $4.94 which suggests that it could grow by 827.23%. Given that CytomX Therapeutics has higher upside potential than Akebia Therapeutics, analysts believe CytomX Therapeutics is more attractive than Akebia Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings AKBAAkebia Therapeutics2 0 0 CTMXCytomX Therapeutics2 2 0 -
Is AKBA or CTMX More Risky?
Akebia Therapeutics has a beta of 0.866, which suggesting that the stock is 13.353% less volatile than S&P 500. In comparison CytomX Therapeutics has a beta of 1.335, suggesting its more volatile than the S&P 500 by 33.546%.
-
Which is a Better Dividend Stock AKBA or CTMX?
Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytomX Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. CytomX Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKBA or CTMX?
Akebia Therapeutics quarterly revenues are $46.5M, which are larger than CytomX Therapeutics quarterly revenues of $38.1M. Akebia Therapeutics's net income of -$22.8M is lower than CytomX Therapeutics's net income of $18.9M. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while CytomX Therapeutics's PE ratio is 1.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 2.17x versus 0.33x for CytomX Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKBAAkebia Therapeutics2.17x -- $46.5M -$22.8M CTMXCytomX Therapeutics0.33x 1.37x $38.1M $18.9M
-
Which has Higher Returns AKBA or IPA?
ImmunoPrecise Antibodies has a net margin of -49.04% compared to Akebia Therapeutics's net margin of -349.88%. Akebia Therapeutics's return on equity of -- beat ImmunoPrecise Antibodies's return on equity of -132.89%.
Company Gross Margin Earnings Per Share Invested Capital AKBAAkebia Therapeutics56.2% -$0.10 -$10.5M IPAImmunoPrecise Antibodies53.57% -$0.46 $17.3M -
What do Analysts Say About AKBA or IPA?
Akebia Therapeutics has a consensus price target of $7.38, signalling upside risk potential of 346.97%. On the other hand ImmunoPrecise Antibodies has an analysts' consensus of $4.00 which suggests that it could grow by 827.43%. Given that ImmunoPrecise Antibodies has higher upside potential than Akebia Therapeutics, analysts believe ImmunoPrecise Antibodies is more attractive than Akebia Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings AKBAAkebia Therapeutics2 0 0 IPAImmunoPrecise Antibodies0 0 0 -
Is AKBA or IPA More Risky?
Akebia Therapeutics has a beta of 0.866, which suggesting that the stock is 13.353% less volatile than S&P 500. In comparison ImmunoPrecise Antibodies has a beta of 0.386, suggesting its less volatile than the S&P 500 by 61.353%.
-
Which is a Better Dividend Stock AKBA or IPA?
Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ImmunoPrecise Antibodies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. ImmunoPrecise Antibodies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKBA or IPA?
Akebia Therapeutics quarterly revenues are $46.5M, which are larger than ImmunoPrecise Antibodies quarterly revenues of $4.3M. Akebia Therapeutics's net income of -$22.8M is lower than ImmunoPrecise Antibodies's net income of -$15.1M. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while ImmunoPrecise Antibodies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 2.17x versus 0.71x for ImmunoPrecise Antibodies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKBAAkebia Therapeutics2.17x -- $46.5M -$22.8M IPAImmunoPrecise Antibodies0.71x -- $4.3M -$15.1M
-
Which has Higher Returns AKBA or LFWD?
Lifeward has a net margin of -49.04% compared to Akebia Therapeutics's net margin of -202.49%. Akebia Therapeutics's return on equity of -- beat Lifeward's return on equity of -81.96%.
Company Gross Margin Earnings Per Share Invested Capital AKBAAkebia Therapeutics56.2% -$0.10 -$10.5M LFWDLifeward24.44% -$1.73 $18.8M -
What do Analysts Say About AKBA or LFWD?
Akebia Therapeutics has a consensus price target of $7.38, signalling upside risk potential of 346.97%. On the other hand Lifeward has an analysts' consensus of $9.00 which suggests that it could grow by 529.37%. Given that Lifeward has higher upside potential than Akebia Therapeutics, analysts believe Lifeward is more attractive than Akebia Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings AKBAAkebia Therapeutics2 0 0 LFWDLifeward1 0 0 -
Is AKBA or LFWD More Risky?
Akebia Therapeutics has a beta of 0.866, which suggesting that the stock is 13.353% less volatile than S&P 500. In comparison Lifeward has a beta of 1.509, suggesting its more volatile than the S&P 500 by 50.926%.
-
Which is a Better Dividend Stock AKBA or LFWD?
Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lifeward offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. Lifeward pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKBA or LFWD?
Akebia Therapeutics quarterly revenues are $46.5M, which are larger than Lifeward quarterly revenues of $7.5M. Akebia Therapeutics's net income of -$22.8M is lower than Lifeward's net income of -$15.3M. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while Lifeward's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 2.17x versus 0.48x for Lifeward. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKBAAkebia Therapeutics2.17x -- $46.5M -$22.8M LFWDLifeward0.48x -- $7.5M -$15.3M
-
Which has Higher Returns AKBA or MCRB?
Seres Therapeutics has a net margin of -49.04% compared to Akebia Therapeutics's net margin of --. Akebia Therapeutics's return on equity of -- beat Seres Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AKBAAkebia Therapeutics56.2% -$0.10 -$10.5M MCRBSeres Therapeutics-- -$0.11 -- -
What do Analysts Say About AKBA or MCRB?
Akebia Therapeutics has a consensus price target of $7.38, signalling upside risk potential of 346.97%. On the other hand Seres Therapeutics has an analysts' consensus of $4.59 which suggests that it could grow by 677.73%. Given that Seres Therapeutics has higher upside potential than Akebia Therapeutics, analysts believe Seres Therapeutics is more attractive than Akebia Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings AKBAAkebia Therapeutics2 0 0 MCRBSeres Therapeutics4 1 0 -
Is AKBA or MCRB More Risky?
Akebia Therapeutics has a beta of 0.866, which suggesting that the stock is 13.353% less volatile than S&P 500. In comparison Seres Therapeutics has a beta of 2.541, suggesting its more volatile than the S&P 500 by 154.129%.
-
Which is a Better Dividend Stock AKBA or MCRB?
Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Seres Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. Seres Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKBA or MCRB?
Akebia Therapeutics quarterly revenues are $46.5M, which are larger than Seres Therapeutics quarterly revenues of --. Akebia Therapeutics's net income of -$22.8M is lower than Seres Therapeutics's net income of -$15.6M. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while Seres Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 2.17x versus 0.74x for Seres Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKBAAkebia Therapeutics2.17x -- $46.5M -$22.8M MCRBSeres Therapeutics0.74x -- -- -$15.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Chewy a Growth Stock to Buy?
It might be a surprise to learn that during the…
Is Realty Income the Best Dividend Stock to Buy Long-Term?
Realty Income (NYSE:O) is a longstanding real estate investment trust…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
50
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
42
KMX alert for Apr 12
CarMax [KMX] is up 2.87% over the past day.
Buy
89
GDXU alert for Apr 12
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 15.9% over the past day.
Sell
30
CRSP alert for Apr 12
CRISPR Therapeutics AG [CRSP] is up 14.59% over the past day.
